👑 CROWN at 7 years.
➡️ Lorlatinib median PFS: still not reached.
7-yr PFS: 55% vs 3%.
HR 0.19.
Event-free at 2 years → 79% still progression-free at year 7.
Zero new brain metastases after month 30. IC HR 0.06. Only 5% discontinued for TRAEs.
I think this is what it is for a meaningful subset of ALK+ patients: functional cure. Really exciting! For me today most patients should be getting lorlatinib 1L for @ALKPositiveinc@LungCancerRx@ASCO #ASCO26
If you’re an #IMG who applied to Hem/Onc fellowship this past cycle, please consider filling out this quick survey.
The more we share our experiences, the better we can understand the challenges we face as #IMGs and support future applicants.
Would really appreciate your input 👇
@HemOncFellows@hemeoncfellow@IMG_Oncologists
10/23 #TumorBoardTuesday @TumorBoardTues@MPishvaian
Importantly, osimertinib is currently the only adjuvant therapy in resected NSCLC to demonstrate a statistically significant overall survival benefit in a biomarker-defined population.
https://t.co/yL2StvOvwG
https://t.co/byVkv8A5QL
From how to read a clinical trial to... How We Read FDG PET/CT: 🩻
https://t.co/A9gVDDqp47
Totally different topic but still very important for oncology
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO@EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
https://t.co/HJhZlsBpU2
Beyond ATRA syndrome →
We used to call it ATRA syndrome.
But the biology is bigger.
ATRA, ATO, IDH1/2 and FLT3 inhibitors all force leukemia to mature.
And when too many cells mature at once:
→ cytokines surge
→ endothelium activates
→ capillary leak begins
Clinical pattern:
Fever + hypoxia + fluid overload ≠ infection → think DS
Key principles:
🔥 Dexamethasone immediately
⚖️ Continue vs HOLD based on severity
🧠 Control the substrate
→ Hydroxyurea first-line
→ Gemtuzumab ozogamicin if needed
Steroids treat the syndrome.
Cytoreduction controls the fuel.
Miss that—and you’re treating smoke, not fire.
#AML #Hemetwitter
🚨🚨🚨
RASOLUTE-302 Ph3 is POSITIVE
"Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW!
AMAZING news for patients with #PancreaticCancer
The RAS Revolution is ON!!
https://t.co/I59NNWRB1O
If eos < 1,500 don’t worry about it! Redefining Hematology Referral Thresholds for Eosinophilia - Patel - European Journal of Haematology https://t.co/xbGQx6tJUZ
Amazing to be a leukemia MD in this day & age. This is the timeline of new💊approvals in AML that I get to show our @MCG_AUG Heme/Onc fellows. The last decade has sure been exciting. What's next? #leusm#MedEd